作者
Shubhadeep D Sinha, Sridevi Perapogu, Sreenivasa Chary S, S Ramesh, Jaimanti Bakshi, Ajit Singh, Abdul Khabeer Ahmed, B Mohan Reddy, Muralidhar Panapakam, Leela Talluri, Ramya Vattipalli
发表日期
2023/11/2
期刊
Journal of Asthma
卷号
60
期号
11
页码范围
2014-2020
出版商
Taylor & Francis
简介
Background
Histamine and cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators in allergic rhinitis (AR). Studies involving other combinations of antihistaminics (Levocetirizine) and highly selective leukotriene receptor antagonist (LTA) (Montelukast) combination have shown additive benefits and are widely prescribed for AR.
Objective
Evaluate the efficacy and safety of Bilastine 20 mg and Montelukast 10 mg fixed-dose combination (FDC) therapy in patients with AR.
Methods
A randomized, double-blind, comparative, parallel, phase III study was conducted to evaluate efficacy and safety of Bilastine 20 mg and Montelukast 10 mg FDC at 16 tertiary care otolaryngology centres in India. Adult patients with AR for one year with IgE antibody positive and 12-h NSS score >36 in 3 days were randomized to receive either Bilastine 20 mg and Montelukast 10 mg or Montelukast 10 mg & Levocetirizine 5 mg tablets …
学术搜索中的文章
SD Sinha, S Perapogu, S Chary S, S Ramesh, J Bakshi… - Journal of Asthma, 2023